Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3349-3359

  Yang, Na ^a   Feng, Shun ^a   Shedden, Kerby ^b   Xie, Xiaolei ^a   Liu, Yashu ^a   Rosser, Charles J ^c   Lubman, David M ^a   Goodison, Steven ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; CELL ADHESION MOLECULE; GLUTAMINYL PEPTIDE CYCLOTRANSFERASE; GLYCOPROTEIN; HEMOPEXIN; HERMES ANTIGEN; OSTEOPONTIN; PROACTIVATOR POLYPEPTIDE; SEROTRANSFERRIN; TAMM HORSFALL GLYCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHROMATOGRAPHY, LIQUID; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; STAINING AND LABELING; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 79956044485     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3121     Document Type: Article

References (53)

1. Jemal A, Siegel R, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374:239-49.
3. Trivedi D, Messing EM. Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria. BMC Urol 2009;9:13.
4. Tetu B. Diagnosis of urothelial carcinoma from urine. Mod Pathol 2009;22 Suppl 2:S53-9.
5. Garcia Castro M, Fernandez Fernandez E, Martin Corriente MC, Garcia Hernandez S, Alvarez-Arguelles CH. Usefulness of urine cytology for bladder carcinoma diagnosis: comparative study with biopsy. Actas Urol Esp 2008;32:904-7.
6. Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 2006;36:172-5.
7. Nakamura K, Kasraeian A, Iczkowski KA, Chang M, Pendleton J, Anai S, et al. Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urol 2009;9:12.
8. Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002;41:284-9. (Pubitemid 35303426)
9. Madeb R, Messing EM. Long-term outcome of home dipstick testing for hematuria. World J Urol 2008;26:19-24.
10. Gutierrez Banos JL, del Henar Rebollo Rodrigo M, Antolin Juarez FM, Garcia BM. Usefulness of the BTA STAT Test for the diagnosis of bladder cancer. Urology 2001;57:685-9.
11. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998;52:398-402. (Pubitemid 28399904)
12. Chang YH, Wu CH, Lee YL, Huang PH, Kao YL, Shiau MY. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer. Urology 2004;64:687-92.
13. Linder S. Cytokeratin markers come of age. Tumour Biol 2007;28:189-95. (Pubitemid 47379291)
14. Gromov P, Moreira JMA, Gromova I, Celis JE. Proteomic strategies in bladder cancer: From tissue to fluid and back. Proteomics Clin Appl 2008;2:974-88.
15. Topsakal M, Karadeniz T, Anac M, Donmezer S, Besisik A. Assessment of fibrin-fibrinogen degradation products (Accu-Dx) test in bladder cancer patients. Eur Urol 2001;39:287-91. (Pubitemid 32245368)
16. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997;158:801-5.
17. Irmak S, Tilki D, Heukeshoven J, Oliveira-Ferrer L, Friedrich M, Huland H, et al. Stage-dependent increase of orosomucoid and zinc-alpha(2)-glycoprotein in urinary bladder cancer. Proteomics 2005;5:4296-304.
18. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66:35-63. (Pubitemid 43049608)
19. Vrooman OP, Witjes JA. Urinary markers in bladder cancer. Eur Urol 2008;53:909-16.
20. Hernandez J, Thompson IM. Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker. Cancer 2004;101:894-904. (Pubitemid 39100420)
21. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med 1994;121:124-32.
22. Kreunin P, Zhao J, Rosser C, Urquidi V, Lubman DM, Goodison S. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res 2007;6:2631-9. (Pubitemid 47122358)
23. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002;74:5383-92. (Pubitemid 35215372)
24. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003;75:4646-58. (Pubitemid 37082259)
25. Old WM, Meyer-Arendt K, Aveline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 2005;4:1487-502. (Pubitemid 41555475)
26. Beissbarth T, Hyde L, Smyth GK, Job C, Boon WM, Tan SS, et al. Statistical modeling of sequencing errors in SAGE libraries. Bioinformatics 2004;20 Suppl 1:i31-9.
27. Decramer S, de Peredo AG, Breuil B, Mischak H, Monsarrat B, Bascands JL, et al. Urine in Clinical Proteomics. Mol Cell Proteomics 2008;7:1850-62.
28. Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol Cell Proteomics 2006;5:1760-71. (Pubitemid 44688186)
29. Pu FS. Urinary excretion of creatinine in normal subjects. Chin Pharm J 1992;44:235-40.
30. Baker SG. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst 2003;95:511-5.
31. Sun Y, Goodison S. Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate 2009;69:1119-27.
32. Yan W, Lee H, Deutsch EW, Lazaro CA, Tang W, Chen E, et al. A dataset of human liver proteins identified by protein profiling via isotope-coded affinity tag (ICAT) and tandem mass spectrometry. Mol Cell Proteomics 2004;3:1039-41. (Pubitemid 40361237)
33. Tantipaiboonwong P, Sinchaikul S, Sriyam S, Phutrakul S, Chen ST. Different techniques for urinary protein analysis of normal and lung cancer patients. Proteomics 2005;5:1140-9. (Pubitemid 40469041)
34. Nabi G, N'Dow J, Hasan TS, Booth IR, Cash P. Proteomic analysis of urine in patients with intestinal segments transposed into the urinary tract. Proteomics 2005;5:1729-33. (Pubitemid 40593278)
35. Orenes-Pinero E, Corton M, Gonzalez-Peramato P, Algaba F, Casal I, Serrano A, et al. Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J Proteome Res 2007;6:4440-8. (Pubitemid 350158519)
36. Saito M, Kimoto M, Araki T, Shimada Y, Fujii R, Oofusa K, et al. Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur Urol 2005;48:865-71. (Pubitemid 41495397)
37. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006;7:230-40. (Pubitemid 43286453)
38. Chen YT, Chen CL, Chen HW, Chung T, Wu CC, Chen CD, et al. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J Proteome Res 2010;9:5803-15.
39. Wang L, Li F, Sun W, Wu S, Wang X, Zhang L, et al. Concanavalin A-captured glycoproteins in healthy human urine. Mol Cell Proteomics 2006;5:560-2.
40. Feng S, Yang N, Pennathur S, Goodison S, Lubman DM. Enrichment of glycoproteins using nanoscale chelating concanavalin A monolithic capillary chromatography. Anal Chem 2009;81:3776-83.
41. Motoyama A, Yates JR, 3rd. Multidimensional LC separations in shotgun proteomics. Anal Chem 2008;80:7187-93.
42. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 2006;312:212-7.
43. Chen EI, Yates JR, 3rd. Cancer proteomics by quantitative shotgun proteomics. Mol Oncol 2007;1:144-59.
44. Veenstra TD. Global and targeted quantitative proteomics for biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci 2007;847:3-11. (Pubitemid 46216196)
45. Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001;19:242-7. (Pubitemid 32220565)
46. Liu H, Sadygov RG, Yates JR, 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004;76:4193-201.
47. Zybailov B, Coleman MK, Florens L, Washburn MP. Correlation of relative abundance ratios derived from peptide ion chromatograms and spectrum counting for quantitative proteomic analysis using stable isotope labeling. Anal Chem 2005;77:6218-24. (Pubitemid 41436955)
48. Patel VJ, Thalassinos K, Slade SE, Connolly JB, Crombie A, Murrell JC, et al. A comparison of labeling and label-free mass spectrometry-based proteomics approaches. J Proteome Res 2009;8:3752-9.
49. Zhu W, Smith JW, Huang CM. Mass spectrometry-based label-free quantitative proteomics. J Biomed Biotechnol 2010;2010:840518.
50. Kreunin P, Yoo C, Urquidi V, Lubman DM, Goodison S. Differential expression of ribosomal proteins in a human metastasis model identified by coupling 2-D liquid chromatography and mass spectrometry. Cancer Genomics Proteomics 2007;4:329-39. (Pubitemid 350067363)
51. Lindor NM, Yang P, Evans I, Schowalter K, De Andrade M, Li J, et al. Alpha-1-antitrypsin deficiency and smoking as risk factors for mismatch repair deficient colorectal cancer: a study from the colon cancer family registry. Mol Genet Metab 2010;99:157-9.
52. Hamrita B, Chahed K, Trimeche M, Guillier CL, Hammann P, Chaieb A, et al. Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas. Clin Chim Acta 2009;404:111-8.
53. Normandin K, Peant B, Le Page C, de Ladurantaye M, Ouellet V, Tonin PN, et al. Protease inhibitor SERPINA1 expression in epithelial ovarian cancer. Clin Exp Metastasis 2010;27:55-69.